https://doi.org/10.1016/S1473-3099(24)00561-9

IF 36.4 1区医学 Q1 INFECTIOUS DISEASES Lancet Infectious Diseases Pub Date : 2024-11-06 DOI:10.1016/s1473-3099(24)00743-6

{"title":"https://doi.org/10.1016/S1473-3099(24)00561-9","authors":"","doi":"10.1016/s1473-3099(24)00743-6","DOIUrl":null,"url":null,"abstract":"Heil EL, McCreary EK. REVISITing treatment of metallo-β-lactamases. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00561-9—In this Comment, two corrections have been made. The correct treatment difference for clinical cure rate at the test-of-cure visit is 2·7% (95% CI –6·6 to 12·4). The loading dose for aztreonam–avibactam was clarified to state it was how the drug was administered in the REVISIT trial. These corrections have been made to the online version as of Nov 6, 2024, and the printed version will be correct..","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"18 1","pages":""},"PeriodicalIF":36.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Infect Dis 2024; published online October 7. https://doi.org/10.1016/S1473-3099(24)00561-9\",\"authors\":\"\",\"doi\":\"10.1016/s1473-3099(24)00743-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heil EL, McCreary EK. REVISITing treatment of metallo-β-lactamases. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00561-9—In this Comment, two corrections have been made. The correct treatment difference for clinical cure rate at the test-of-cure visit is 2·7% (95% CI –6·6 to 12·4). The loading dose for aztreonam–avibactam was clarified to state it was how the drug was administered in the REVISIT trial. These corrections have been made to the online version as of Nov 6, 2024, and the printed version will be correct..\",\"PeriodicalId\":49923,\"journal\":{\"name\":\"Lancet Infectious Diseases\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":36.4000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s1473-3099(24)00743-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s1473-3099(24)00743-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

Heil EL, McCreary EK.重新审视金属-β-内酰胺酶的治疗。https://doi.org/10.1016/S1473-3099(24)00561-9 在本评论中，有两处更正。治愈试验时临床治愈率的正确治疗差异为 2-7%（95% CI -6-6~12-4）。澄清了阿兹曲南-阿维巴坦的负荷剂量，以说明REVISIT试验中的给药方式。截至 2024 年 11 月 6 日，在线版本已进行了这些更正，印刷版本也将进行更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Correction to Lancet Infect Dis 2024; published online October 7. https://doi.org/10.1016/S1473-3099(24)00561-9

Heil EL, McCreary EK. REVISITing treatment of metallo-β-lactamases. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00561-9—In this Comment, two corrections have been made. The correct treatment difference for clinical cure rate at the test-of-cure visit is 2·7% (95% CI –6·6 to 12·4). The loading dose for aztreonam–avibactam was clarified to state it was how the drug was administered in the REVISIT trial. These corrections have been made to the online version as of Nov 6, 2024, and the printed version will be correct..

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Infectious Diseases 医学-传染病学

CiteScore

60.90

自引率

0.70%

发文量

1064

审稿时长

6-12 weeks

期刊介绍： The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.